Key Takeaways
- Life Biosciences reported that its ER-100 eye therapy was well tolerated through Day 56 in all three glaucoma patients in its Phase 1 trial.
- Two of the three patients showed preliminary improvement on visual field testing, a 67 percent share of the small group.
- The company's independent safety board recommended moving the glaucoma trial to a higher dose level, a step that depends on safety data rather than efficacy.
Life Biosciences reported interim data from its Phase 1 clinical trial of ER-100 on October 8, 2026, showing that a single eye injection with daily oral doxycycline was tolerated through Day 56 in three participants with open-angle glaucoma. Two of those three participants showed preliminary signals of improvement in visual field testing, according to the company's press release.
How the ER-100 Eye Therapy Is Designed to Work
ER-100 is a gene therapy that delivers three genes, Oct4, Sox2 and Klf4 (OSK), directly to the eye, according to Lifespan Magazine. Life Bio says the three transcription factors are meant to restore older and damaged cells to a younger, healthier state. In the trial, each patient received an intravitreal injection, which places the drug inside the eye, and then took a daily dose of doxycycline to activate the treatment.
The disease target matters for the stakes. Glaucoma affects over 10 percent of people over 80 worldwide, and current therapies mainly slow further vision loss rather than restore vision already lost, the magazine reports. That gap is why a treatment that might improve vision, not just stop decline, draws attention.
What the Visual Field Numbers Show
The visual field test measures how many points across a patient's field of vision a person can detect light at. In each of the two patients who improved, at least 28 percent of the tested points showed an improvement of more than 4 decibels, the release says. Two of three is about 67 percent of the group, a ratio the company's headline does not state.
The safety side is also moving. An independent Data Safety Monitoring Board recommended escalating to Dose Level 2 in the glaucoma patients. The next group will receive 600 billion viral genomes, three times the dose used in the first group, Lifespan reports. Escalating a dose is a safety decision, so the step signals that the early tolerability data were acceptable to the board.
Why Three Patients Cannot Show a Treatment Works
The company is clear about the study's purpose. Its Chief Scientific Officer, Sharon Rosenzweig-Lipson, said in the release: "While this Phase 1 study is designed to evaluate safety and tolerability, the preliminary observations of visual field improvements in two participants are encouraging as we continue to advance the ER-100 program."
Three participants is a very small group. The results can show that the treatment was tolerated at the first dose and that two people's visual fields changed in the right direction. They cannot show how often that happens, how long any gain lasts, or whether it beats existing care. The next round of results at the higher dose should show whether the early findings hold.
People Also Ask
What is ER-100?
ER-100 is an experimental gene therapy from Life Biosciences that delivers Oct4, Sox2 and Klf4 genes to the eye. The company is testing it in people with open-angle glaucoma and a second optic nerve condition called non-arteritic anterior ischemic optic neuropathy. Life Biosciences reported the first in-human interim results for ER-100 on October 8, 2026.
Did the ER-100 glaucoma trial show that the treatment restores vision?
The trial did not show that. Life Biosciences reported that two of the three glaucoma patients showed preliminary improvement on visual field testing. The company's chief scientist said the study is designed to evaluate safety and tolerability, so the vision results are early observations, not proof of a treatment effect.
How many people were in the ER-100 glaucoma trial results?
The interim results covered three participants with open-angle glaucoma who received a single intravitreal dose of ER-100. All three were tolerated through Day 56, and two showed visual field improvement. The next dose group will receive three times the first dose, 600 billion viral genomes.
What happens next in the ER-100 trial?
The Data Safety Monitoring Board recommended moving to Dose Level 2, so the trial continues at the higher dose. The next round of results will show whether the early safety findings and vision improvements hold up at that dose.
Sources: GlobeNewswire, Lifespan Magazine.